ITM, Helmholtz Munich, and University Hospital Münster Report Initial Dosing of First Participant in Phase I Research Trial for Glioblastoma.

GPCRs, as key signal transduction molecules on the cell surface, regulate various physiological processes and constitute one-third of the targets for clinical drug applications.

Voydeya has been sanctioned in the EU as a supplementary treatment alongside ravulizumab or eculizumab for adults with PNH who still suffer from persistent haemolytic anaemia.

LD50 (median lethal dose) is a commonly used indicator in toxicology to describe the toxicity of toxic substances or radiation.

The recent phase 3 LUNA 3 trial demonstrated that 400 mg of rilzabrutinib taken orally twice daily effectively achieved the primary goal of sustaining platelet response in adults with persistent or chronic immune thrombocytopenia.

ImmunityBio Receives FDA Nod for ANKTIVA®, a Novel IL-15 Receptor Stimulator, for Treating BCG-Resistant Non-Muscle Invasive Bladder Cancer.

Neurogene Set to Reveal NGN-401 Gene Therapy Safety Results from Early Stage Trial for Rett Syndrome during ASGCT Conference.

Adicet Bio presents preclinical findings indicating IND preparedness for ADI-270 during a talk at the 27th Annual ASGCT Meeting.

April 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

ASLAN Pharmaceuticals Reports Encouraging Preliminary Outcomes from a Phase 2 Trial of Eblasakimab in Patients with Atopic Dermatitis Previously Treated with Dupilumab.

At present, 13 types of ADCs have been approved by the United States Food and Drug Administration (FDA), with over 200 additional ADCs at various stages of clinical trials.

Kintor Pharmaceutical Limited announced that its innovative proteolysis targeting chimera compound, GT20029, targeting the androgen receptor (AR), has achieved the primary endpoint in a phase II trial in China.